Mineralys Therapeutics, Inc. - 8-K Filing
Mineralys Therapeutics entered into an underwriting agreement on June 3, 2026, with BofA Securities, Inc., Goldman Sachs & Co. LLC, and Evercore Group L.L.C. to issue and sell 5,660,378 shares of common stock at $26.50 per share, resulting in expected net proceeds of approximately $142.5 million after underwriting discounts and expenses. The offering is set to close on June 4, 2026. (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $MLYS